

RÉSUMÉ DIGEST

ACT 160 (SB 48)

2024 Regular Session

Talbot

Existing law requires any health coverage plan renewed, delivered, or issued for delivery in this state to include coverage for biomarker testing for the purpose of the diagnosis, treatment, appropriate management, or ongoing monitoring of an individual's disease or condition when the test provides clinical utility as demonstrated by medical and scientific evidence, including any one of the following:

- (1) Labeled indications for diagnostic tests approved or cleared by the U.S. Food and Drug Administration (FDA) or indicated diagnostic tests for a drug approved by the FDA.
- (2) Warnings and precautions listed on a FDA-approved drug label.
- (3) National Coverage Determinations of the Centers for Medicare and Medicaid Services or Local Coverage Determinations of Medicare Administrative Contractors.
- (4) Nationally recognized clinical practice guidelines.

Prior law required the coverage for biomarker testing be made effective when specific appropriation was made.

New law repeals prior law.

New law applies to any new policy, contract, program, or health coverage plan issued on or after Jan. 1, 2025.

Effective May 23, 2024.

(Amends Section 3 of Act No. 324 of 2023 R.S.)